Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes.
Evangelos K OikonomouMarc A SuchardDarren K McGuireRohan KheraPublished in: Diabetes care (2022)
We present an evidence-based, machine learning-guided algorithm to personalize the prescription of SGLT2 inhibitors for patients with type 2 diabetes for ASCVD effects.